The Serum Institute of India (SII) is the world's largest vaccine maker by volume, and has been at the forefront of producing the lower-cost AstraZeneca coronavirus shot.
India decided to delay big exports of the shots made in its territory by the Serum Institute of India (SII) to make sure it could meet local demand, two sources told Reuters last week.
The African Union had planned to vaccinate 20%-30% of the continent's population by the end of the year he said. "If the vaccines are delayed we are unlikely to meet our target," he added.
India's move will affect supplies to the GAVI/WHO-backed global COVAX vaccine-sharing facility, through which 64 lower-income countries including Indonesia are supposed to get doses from SII.
"This definitely will affect (the vaccination process) because in April we only have around 7 million doses from Sinovac," Budi said.
Adar Poonawalla, the chief executive of Serum, said in January that the vaccine, named Corovax, was expected to be launched by June.
"It has been tested against African and UK variants of #COVID19 and has an overall efficacy of 89%," tweeted Poonawalla, whose Serum Institute is the world's largest manufacturer of vaccines.
Bangladesh is also due to get a total of 68 million doses of vaccines from a WHO-backed alliance, with the first shipment of around 10 million doses expected by June, Mannan said.
"We have not ordered for any additional doses. As of now our total order is for 30 million doses," Beximco Pharmaceuticals' Chief Operating Officer Rabbur Reza told Reuters.
Trudeau said the months-long protests by farmers on the outskirts of Delhi were concerning, drawing a rebuke from the Indian government which said it was an internal matter.
Modi also said India would do its best to supply COVID-19 vaccines sought by Canada.
UNICEF chief Henrietta Fore said the shots would be delivered over a number of years at the cost of about $3 per dose for low- and middle-income countries.
They would be produced by Serum under a technology transfer agreement, she said in a briefing.
SII, the world's biggest vaccine maker, has capacity to produce roughly 2.4 million doses per day at its campus in Pune, western India.
Verity Pharmaceuticals is providing important support to Serum Institute of India related to its regulatory registration, importation and distribution of the vaccine in Canada, pending Health Canada approval.
Negotiations are underway with an Indian manufacturer, Serum Institute, which can produce the American Novovax vaccine and has the ability to produce the AstraZeneca vaccine at the moment.
India will initially only ship the AstraZeneca vaccine, made by The Serum Institute,
The first batch of exports will be shipped to the tiny nation of Bhutan, said the officials, who asked not to be named as the plans are not public.
India has received requests from dozens of nations, including urgent appeals from Brazil, to begin exports of the vaccine from the SII centre in the western city of Pune.
The South Asian country of more than 160 million in November signed a deal with the Serum Institute of India to buy 30 million doses of the vaccine developed by British drugmaker AstraZeneca.
The vaccine will be first applied on the health workers and it will be monitored for the next seven days. After that, we'll begin the vaccination across the country in the first week of February.
Both companies respect the great work being carried out by each other and put behind us the miscommunication and misunderstanding caused during the past week.
India's drugs regulator on Sunday approved for emergency use a vaccine developed by AstraZeneca and Oxford University.